Figure 1.

Glucose lowering efficacy the SGLT-2 inhibitors dapagliflozin (10 mg once-daily) is reduced with declining eGFR. This graph represents pooled data from monotherapy as well as add-on therapy studies in patients with type 2 diabetes. Dapagliflozin leads to a lesser placebo-corrected reduction in HbA1c in patients with moderate renal impairment (eGFR ≥30 and <60 mL/min per 1.73 m²) at baseline. Similar effects have been observed with canagliflozin (17) and empagliflozin (18). 95% CI, 95% confidence interval; HbA1c, hemoglobin A1c. Modified from ref. 51, with permission.